Butterfly Medical has also submitted a premarket approval application to the FDA.
|Articles|February 15, 2004
In radical prostatectomy, 'the future is robotic'
Las Vegas--The development of a robot-assisted method for laparoscopic radical prostatectomy could lessen morbidity, cut recovery times, and shorten the learning curve for urologists who have not been trained in the procedure.
Advertisement
Advertisement
Related to this article
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Butterfly Prostatic Retraction Device granted EU MDR certification for BPH
3
Matching mCSPC treatment to the patient, not just the trial data
4
Variation in PSMA PET Adoption for Prostate Cancer Care
5